Hsbc Holdings PLC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Hsbc Holdings PLC increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 66.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,690 shares of the company's stock after purchasing an additional 15,465 shares during the period. Hsbc Holdings PLC's holdings in IDEAYA Biosciences were worth $980,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IDYA. R Squared Ltd purchased a new stake in shares of IDEAYA Biosciences in the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. raised its stake in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after acquiring an additional 853 shares during the last quarter. KBC Group NV lifted its holdings in IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after buying an additional 1,923 shares during the period. Cibc World Markets Corp purchased a new position in IDEAYA Biosciences during the fourth quarter valued at $203,000. Finally, Mariner LLC boosted its stake in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after purchasing an additional 869 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA traded down $0.39 on Friday, hitting $17.79. 204,757 shares of the stock traded hands, compared to its average volume of 981,927. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -5.39 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42. The business's fifty day moving average is $17.77 and its two-hundred day moving average is $22.77.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the company earned ($0.53) EPS. Analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IDYA shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Stephens reissued an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.